Oropharyngeal Cancer (Oncology) - Drugs In Development, 2021

August 2021 | 978 pages | ID: O5B2DDA4A808EN
Global Markets Direct

Abstracts

Oropharyngeal Cancer (Oncology) - Drugs In Development, 2021

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Oropharyngeal Cancer - Drugs In Development, 2021, provides an overview of the Oropharyngeal Cancer (Oncology) pipeline landscape.Oropharyngeal cancer is a disease which malignant cells form in the tissue of oropharynx. Oropharynx is a middle part of the throat which includes the base of the tongue, the tonsils, the soft palate, and the walls of the pharynx. Oropharyngeal cancers can be divided into two types, HPV-positive, which are related to human papillomavirus infection, and HPV-negative cancers, which are usually linked to alcohol or tobacco use.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Oropharyngeal Cancer - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Oropharyngeal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Oropharyngeal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Oropharyngeal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed and Preclinical stages are 6, 30, 19, 2, 1 and 8 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.

Oropharyngeal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Oropharyngeal Cancer (Oncology).
• The pipeline guide reviews pipeline therapeutics for Oropharyngeal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Oropharyngeal Cancer (Oncology) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Oropharyngeal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Oropharyngeal Cancer (Oncology)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Oropharyngeal Cancer (Oncology).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Oropharyngeal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Oropharyngeal Cancer - Overview
Oropharyngeal Cancer - Therapeutics Development
Oropharyngeal Cancer - Therapeutics Assessment
Oropharyngeal Cancer - Companies Involved in Therapeutics Development
Oropharyngeal Cancer - Drug Profiles
Oropharyngeal Cancer - Dormant Projects
Oropharyngeal Cancer - Discontinued Products
Oropharyngeal Cancer - Product Development Milestonesh
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Oropharyngeal Cancer, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Oropharyngeal Cancer - Pipeline by AbbVie Inc, 2021
Oropharyngeal Cancer - Pipeline by Advaxis Inc, 2021
Oropharyngeal Cancer - Pipeline by AMI Onco Theranostics LLC, 2021
Oropharyngeal Cancer - Pipeline by Anteris Technologies Ltd, 2021
Oropharyngeal Cancer - Pipeline by Ascenta Therapeutics Inc, 2021
Oropharyngeal Cancer - Pipeline by Astex Pharmaceuticals Inc, 2021
Oropharyngeal Cancer - Pipeline by AstraZeneca Plc, 2021
Oropharyngeal Cancer - Pipeline by Bayer AG, 2021
Oropharyngeal Cancer - Pipeline by Biomimetix JV LLC, 2021
Oropharyngeal Cancer - Pipeline by Boehringer Ingelheim International GmbH, 2021
Oropharyngeal Cancer - Pipeline by Bristol-Myers Squibb Co, 2021
Oropharyngeal Cancer - Pipeline by Brooklyn ImmunoTherapeutics Inc, 2021
Oropharyngeal Cancer - Pipeline by Checkmate Pharmaceuticals Inc, 2021
Oropharyngeal Cancer - Pipeline by Compugen Ltd, 2021
Oropharyngeal Cancer - Pipeline by Corvus Pharmaceuticals Inc, 2021
Oropharyngeal Cancer - Pipeline by CSPC Pharmaceutical Group Ltd, 2021
Oropharyngeal Cancer - Pipeline by Cue Biopharma Inc, 2021
Oropharyngeal Cancer - Pipeline by Dracen Pharmaceuticals Inc, 2021
Oropharyngeal Cancer - Pipeline by Eisai Co Ltd, 2021
Oropharyngeal Cancer - Pipeline by EpicentRx Inc, 2021
Oropharyngeal Cancer - Pipeline by Exelixis Inc, 2021
Oropharyngeal Cancer - Pipeline by F-star Therapeutics Inc, 2021
Oropharyngeal Cancer - Pipeline by F. Hoffmann-La Roche Ltd, 2021
Oropharyngeal Cancer - Pipeline by Genentech USA Inc, 2021
Oropharyngeal Cancer - Pipeline by Genexine Inc, 2021
Oropharyngeal Cancer - Pipeline by Gilead Sciences Inc, 2021
Oropharyngeal Cancer - Pipeline by GlaxoSmithKline Plc, 2021
Oropharyngeal Cancer - Pipeline by Hookipa Pharma Inc, 2021
Oropharyngeal Cancer - Pipeline by I-Mab, 2021
Oropharyngeal Cancer - Pipeline by IMV Inc, 2021
Oropharyngeal Cancer - Pipeline by Incyte Corp, 2021
Oropharyngeal Cancer - Pipeline by Innate Pharma SA, 2021
Oropharyngeal Cancer - Pipeline by ISA Pharmaceuticals BV, 2021
Oropharyngeal Cancer - Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2021
Oropharyngeal Cancer - Pipeline by Mabpharm Ltd, 2021
Oropharyngeal Cancer - Pipeline by Merck & Co Inc, 2021
Oropharyngeal Cancer - Pipeline by Merck KGaA, 2021
Oropharyngeal Cancer - Pipeline by Moderna Inc, 2021
Oropharyngeal Cancer - Pipeline by Ono Pharmaceutical Co Ltd, 2021
Oropharyngeal Cancer - Pipeline by Pfizer Inc, 2021
Oropharyngeal Cancer - Pipeline by PNP Therapeutics Inc, 2021
Oropharyngeal Cancer - Pipeline by Precigen Inc, 2021
Oropharyngeal Cancer - Pipeline by Regeneron Pharmaceuticals Inc, 2021
Oropharyngeal Cancer - Dormant Projects, 2021
Oropharyngeal Cancer - Discontinued Products, 2021

List Of Figures

LIST OF FIGURES

Number of Products under Development for Oropharyngeal Cancer, 2021
Number of Products under Development by Companies, 2021
Number of Products by Top 10 Targets, 2021
Number of Products by Stage and Top 10 Targets, 2021
Number of Products by Top 10 Mechanism of Actions, 2021
Number of Products by Stage and Top 10 Mechanism of Actions, 2021
Number of Products by Top 10 Routes of Administration, 2021
Number of Products by Stage and Top 10 Routes of Administration, 2021
Number of Products by Top 10 Molecule Types, 2021
Number of Products by Stage and Top 10 Molecule Types, 2021